98%
921
2 minutes
20
This review aimed to synthesise existing literature on the efficacy of personalised or precision nutrition (PPN) interventions, including medical nutrition therapy (MNT), in improving outcomes related to glycaemic control (HbA1c, post-prandial glucose [PPG], and fasting blood glucose), anthropometry (weight, BMI, and waist circumference [WC]), blood lipids, blood pressure (BP), and dietary intake among adults with prediabetes or metabolic syndrome (MetS). Six databases were systematically searched (Scopus, Medline, Embase, CINAHL, PsycINFO, and Cochrane) for randomised controlled trials (RCTs) published from January 2000 to 16 April 2023. The Academy of Nutrition and Dietetics Quality Criteria were used to assess the risk of bias. Seven RCTs ( = 873), comprising five PPN and two MNT interventions, lasting 3-24 months were included. Consistent and significant improvements favouring PPN and MNT interventions were reported across studies that examined outcomes like HbA1c, PPG, and waist circumference. Results for other measures, including fasting blood glucose, HOMA-IR, blood lipids, BP, and diet, were inconsistent. Longer, more frequent interventions yielded greater improvements, especially for HbA1c and WC. However, more research in studies with larger sample sizes and standardised PPN definitions is needed. Future studies should also investigate combining MNT with contemporary PPN factors, including genetic, epigenetic, metabolomic, and metagenomic data.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11124316 | PMC |
http://dx.doi.org/10.3390/nu16101479 | DOI Listing |
Background: The growing approval and use of digital therapeutics (DTx) for managing chronic diseases, such as diabetes, has prompted questions about their effectiveness.
Objective: This systematic review and meta-analysis aimed to report the effectiveness of DTx interventions in the management of patients with type 1 diabetes, type 2 diabetes, and prediabetes.
Methods: Data sources, including Web of Science, MEDLINE, Embase, and the Cochrane Library, were searched from inception to July 30, 2023.
J Eval Clin Pract
September 2025
St. Luke's Health System, Boise, Idaho, USA.
Introduction: Voucher-based food as medicine programs have become a common method to help reduce the burden of chronic disease. While recent studies find these programs reduce HbA1c, few of these studies included a comparison group.
Objective: This article evaluates the impact of a clinically based voucher program on HbA1c of diabetic patients.
AJPM Focus
October 2025
Department of Public Health Sciences, Penn State College of Medicine, Hershey, Pennsylvania.
Introduction: Prediabetes is prevalent and commonly progresses to diabetes when unaddressed. Prediabetes progression is preventable, yet prediabetes unawareness jeopardizes timely intervention. This study examines barriers and enablers of prediabetes awareness, and describes its influence on diet and physical activity.
View Article and Find Full Text PDFHepatol Commun
September 2025
Department of Internal Medicine, Karsh Division of Gastroenterology and Hepatology, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Background: Steatotic liver diseases (SLDs) and their subcategories-metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic dysfunction and alcohol-associated liver disease (MetALD), and alcohol-associated liver disease (ALD)-significantly contribute to liver-related and extrahepatic morbidity and mortality. This project aimed to assess the landscape of SLDs and clinically significant fibrosis (CSF) before (2017-2020) and during (2021-2023) the COVID-19 pandemic.
Methods: Using National Health and Nutrition Examination Survey (NHANES) data, we analyzed 8965 prepandemic and 6337 pandemic participants aged ≥18 years.
JAMA Psychiatry
September 2025
Department of Endocrinology, Odense University Hospital, Odense, Denmark.
Importance: Patients with schizophrenia have reduced life expectancy due to cardiovascular disease and obesity-related type 2 diabetes, exacerbated by second-generation antipsychotic (SGA) medication. Existing interventions have shown limited effect.
Objectives: To assess the effect of the once-weekly glucagon-like peptide-1 receptor agonist semaglutide in SGA-treated adults (aged 18-60 years) with schizophrenia, prediabetes (glycosylated hemoglobin A1c [HbA1c], 5.